BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 34131282)

  • 1. A novel leukemic route of mutant NPM1 through nuclear import of the overexpressed long noncoding RNA LONA.
    Gourvest M; De Clara E; Wu HC; Touriol C; Meggetto F; De Thé H; Pyronnet S; Brousset P; Bousquet M
    Leukemia; 2021 Oct; 35(10):2784-2798. PubMed ID: 34131282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HOXBLINC long non-coding RNA activation promotes leukemogenesis in NPM1-mutant acute myeloid leukemia.
    Zhu G; Luo H; Feng Y; Guryanova OA; Xu J; Chen S; Lai Q; Sharma A; Xu B; Zhao Z; Feng R; Ni H; Claxton D; Guo Y; Mesa RA; Qiu Y; Yang FC; Li W; Nimer SD; Huang S; Xu M
    Nat Commun; 2021 Mar; 12(1):1956. PubMed ID: 33782403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant NPM1-regulated lncRNA HOTAIRM1 promotes leukemia cell autophagy and proliferation by targeting EGR1 and ULK3.
    Jing Y; Jiang X; Lei L; Peng M; Ren J; Xiao Q; Tao Y; Tao Y; Huang J; Wang L; Tang Y; Yang Z; Yang Z; Zhang L
    J Exp Clin Cancer Res; 2021 Oct; 40(1):312. PubMed ID: 34615546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1.
    Balusu R; Fiskus W; Rao R; Chong DG; Nalluri S; Mudunuru U; Ma H; Chen L; Venkannagari S; Ha K; Abhyankar S; Williams C; McGuirk J; Khoury HJ; Ustun C; Bhalla KN
    Blood; 2011 Sep; 118(11):3096-106. PubMed ID: 21719597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant NPM1 Maintains the Leukemic State through HOX Expression.
    Brunetti L; Gundry MC; Sorcini D; Guzman AG; Huang YH; Ramabadran R; Gionfriddo I; Mezzasoma F; Milano F; Nabet B; Buckley DL; Kornblau SM; Lin CY; Sportoletti P; Martelli MP; Falini B; Goodell MA
    Cancer Cell; 2018 Sep; 34(3):499-512.e9. PubMed ID: 30205049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice.
    Martelli MP; Pettirossi V; Thiede C; Bonifacio E; Mezzasoma F; Cecchini D; Pacini R; Tabarrini A; Ciurnelli R; Gionfriddo I; Manes N; Rossi R; Giunchi L; Oelschlägel U; Brunetti L; Gemei M; Delia M; Specchia G; Liso A; Di Ianni M; Di Raimondo F; Falzetti F; Del Vecchio L; Martelli MF; Falini B
    Blood; 2010 Nov; 116(19):3907-22. PubMed ID: 20634376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Curious Novel Combination of
    Venanzi A; Rossi R; Martino G; Annibali O; Avvisati G; Mameli MG; Sportoletti P; Tiacci E; Falini B; Martelli MP
    Genes (Basel); 2021 Sep; 12(9):. PubMed ID: 34573408
    [No Abstract]   [Full Text] [Related]  

  • 8. The human nucleophosmin 1 mutation A inhibits myeloid differentiation of leukemia cells by modulating miR-10b.
    Zou Q; Tan S; Yang Z; Wang J; Xian J; Zhang S; Jin H; Yang L; Wang L; Zhang L
    Oncotarget; 2016 Nov; 7(44):71477-71490. PubMed ID: 27669739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia.
    Nabbouh AI; Hleihel RS; Saliba JL; Karam MM; Hamie MH; Wu HJM; Berthier CP; Tawil NM; Bonnet PA; Deleuze-Masquefa C; El Hajj HA
    Cancer; 2017 May; 123(9):1662-1673. PubMed ID: 28055106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF.
    Bolli N; De Marco MF; Martelli MP; Bigerna B; Pucciarini A; Rossi R; Mannucci R; Manes N; Pettirossi V; Pileri SA; Nicoletti I; Falini B
    Leukemia; 2009 Mar; 23(3):501-9. PubMed ID: 19005479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients.
    De Clara E; Gourvest M; Ma H; Vergez F; Tosolini M; Dejean S; Demur C; Delabesse E; Recher C; Touriol C; Martelli MP; Falini B; Brousset P; Bousquet M
    Haematologica; 2017 Oct; 102(10):1718-1726. PubMed ID: 28679652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of small molecule inhibitor NSC348884 on nucleophosmin 1-mutated acute myeloid leukemia cells.
    Zhu JF; Han LL; Ma Y; Wang YX; Zhang F
    Eur Rev Med Pharmacol Sci; 2023 Oct; 27(19):9145-9151. PubMed ID: 37843328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleophosmin mutations in acute myeloid leukemia: a tale of protein unfolding and mislocalization.
    Federici L; Falini B
    Protein Sci; 2013 May; 22(5):545-56. PubMed ID: 23436734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The long non-coding RNA HOXB-AS3 regulates ribosomal RNA transcription in NPM1-mutated acute myeloid leukemia.
    Papaioannou D; Petri A; Dovey OM; Terreri S; Wang E; Collins FA; Woodward LA; Walker AE; Nicolet D; Pepe F; Kumchala P; Bill M; Walker CJ; Karunasiri M; Mrózek K; Gardner ML; Camilotto V; Zitzer N; Cooper JL; Cai X; Rong-Mullins X; Kohlschmidt J; Archer KJ; Freitas MA; Zheng Y; Lee RJ; Aifantis I; Vassiliou G; Singh G; Kauppinen S; Bloomfield CD; Dorrance AM; Garzon R
    Nat Commun; 2019 Nov; 10(1):5351. PubMed ID: 31767858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
    Falini B; Bolli N; Liso A; Martelli MP; Mannucci R; Pileri S; Nicoletti I
    Leukemia; 2009 Oct; 23(10):1731-43. PubMed ID: 19516275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NPM1-mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions.
    Falini B
    Am J Hematol; 2023 Sep; 98(9):1452-1464. PubMed ID: 37317978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nucleophosmin 1 Mutations in Acute Myeloid Leukemia.
    Zarka J; Short NJ; Kanagal-Shamanna R; Issa GC
    Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32545659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deguelin induced differentiation of mutated NPM1 acute myeloid leukemia in vivo and in vitro.
    Zhang X; Zhao Z; Yi S; Wen L; He J; Hu J; Ruan J; Fang J; Chen Y
    Anticancer Drugs; 2017 Aug; 28(7):723-738. PubMed ID: 28471807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When the good go bad: Mutant NPM1 in acute myeloid leukemia.
    Kunchala P; Kuravi S; Jensen R; McGuirk J; Balusu R
    Blood Rev; 2018 May; 32(3):167-183. PubMed ID: 29157973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miRNA-mRNA Profiling Reveals Prognostic Impact of
    Gadewal N; Kumar R; Aher S; Gardane A; Gaur T; Varma AK; Khattry N; Hasan SK
    Oncol Res; 2020 May; 28(3):321-330. PubMed ID: 32059753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.